VSIR and prostate carcinoma: After the treatment with ipilimumab, the expression of VISTA is raised higher on CD68+ macrophages, CD4+ T cells and CD8+ T cells, given that VISTA is the inhibitory immune checkpoint in prostate cancer, no matter whether for metastatic or localized.